Forbes J M & Co. LLP Purchases 392,832 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Forbes J M & Co. LLP grew its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 56.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,094,564 shares of the company's stock after purchasing an additional 392,832 shares during the quarter. Forbes J M & Co. LLP owned about 1.89% of Ginkgo Bioworks worth $6,239,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DNA. Bank of New York Mellon Corp boosted its position in Ginkgo Bioworks by 48.2% during the fourth quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company's stock worth $226,000 after purchasing an additional 7,503 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Ginkgo Bioworks by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 233,717 shares of the company's stock worth $2,295,000 after purchasing an additional 17,372 shares during the period. KLP Kapitalforvaltning AS bought a new position in Ginkgo Bioworks during the fourth quarter worth about $46,000. EntryPoint Capital LLC bought a new position in Ginkgo Bioworks during the fourth quarter worth about $262,000. Finally, Headlands Technologies LLC bought a new position in Ginkgo Bioworks during the fourth quarter worth about $173,000. Institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Price Performance

NYSE:DNA traded down $0.95 on Friday, reaching $13.96. 1,540,989 shares of the company's stock were exchanged, compared to its average volume of 2,006,462. The stock has a fifty day simple moving average of $9.50 and a 200-day simple moving average of $9.24. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $16.85. The firm has a market cap of $816.81 million, a price-to-earnings ratio of -1.52 and a beta of 1.48.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 198.84% and a negative return on equity of 52.35%. The firm had revenue of $48.32 million during the quarter, compared to the consensus estimate of $38.70 million. As a group, sell-side analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.